CO6862100A2 - Péptidos tomm34 y vacunas que los incluyen - Google Patents
Péptidos tomm34 y vacunas que los incluyenInfo
- Publication number
- CO6862100A2 CO6862100A2 CO13155530A CO13155530A CO6862100A2 CO 6862100 A2 CO6862100 A2 CO 6862100A2 CO 13155530 A CO13155530 A CO 13155530A CO 13155530 A CO13155530 A CO 13155530A CO 6862100 A2 CO6862100 A2 CO 6862100A2
- Authority
- CO
- Colombia
- Prior art keywords
- vaccines
- tomm34
- peptides
- tomm34 peptides
- Prior art date
Links
- 101150092178 Tomm34 gene Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41918110P | 2010-12-02 | 2010-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6862100A2 true CO6862100A2 (es) | 2014-02-10 |
Family
ID=46171433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13155530A CO6862100A2 (es) | 2010-12-02 | 2013-07-02 | Péptidos tomm34 y vacunas que los incluyen |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9125849B2 (OSRAM) |
| EP (1) | EP2646546B1 (OSRAM) |
| JP (2) | JP6064186B2 (OSRAM) |
| KR (1) | KR102004900B1 (OSRAM) |
| CN (2) | CN103339253B (OSRAM) |
| AR (1) | AR084095A1 (OSRAM) |
| AU (1) | AU2011336019B2 (OSRAM) |
| BR (1) | BR112013013158B1 (OSRAM) |
| CA (1) | CA2819463C (OSRAM) |
| CO (1) | CO6862100A2 (OSRAM) |
| DK (1) | DK2646546T3 (OSRAM) |
| EA (1) | EA028216B1 (OSRAM) |
| ES (1) | ES2677118T3 (OSRAM) |
| IL (1) | IL226068B (OSRAM) |
| MX (1) | MX344586B (OSRAM) |
| MY (1) | MY166516A (OSRAM) |
| NZ (1) | NZ611361A (OSRAM) |
| PH (1) | PH12013501105A1 (OSRAM) |
| SG (2) | SG10201509823WA (OSRAM) |
| TW (1) | TWI618541B (OSRAM) |
| UA (1) | UA110119C2 (OSRAM) |
| WO (1) | WO2012073459A1 (OSRAM) |
| ZA (1) | ZA201303886B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013317194B2 (en) | 2012-09-11 | 2018-07-12 | Oncotherapy Science, Inc. | UBE2T peptides and vaccines containing the same |
| JP2015228191A (ja) * | 2014-06-03 | 2015-12-17 | カシオ計算機株式会社 | コンテンツ出力システム、コンテンツ出力方法、コンテンツ出力プログラム、および通信端末 |
| WO2017150084A1 (ja) * | 2016-02-29 | 2017-09-08 | 京セラドキュメントソリューションズ株式会社 | 電子機器およびマーカー処理方法 |
| MX2019008878A (es) | 2017-01-25 | 2020-02-13 | Ose Immunotherapeutics | Metodo para fabricar una emulsion estable para suministro de peptidos. |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5785973A (en) | 1988-02-01 | 1998-07-28 | Praxis Biologics, Inc. | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines |
| US5539084A (en) | 1989-02-17 | 1996-07-23 | Coselco Mimotopes Pty. Ltd. | Method for the use and synthesis of peptides |
| CA2158655A1 (en) * | 1993-03-19 | 1994-09-29 | Max L. Birnstiel | Process for preparing cancer vaccines |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| AU2926601A (en) | 2000-01-03 | 2001-07-16 | Argonex Pharmaceuticals, Inc. | C-ski oncogene-derived peptides for prevention, treatment, and diagnosis of cancer |
| US7700359B2 (en) | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
| US20040181344A1 (en) | 2002-01-29 | 2004-09-16 | Massachusetts Institute Of Technology | Systems and methods for providing diagnostic services |
| JP4594085B2 (ja) * | 2002-06-06 | 2010-12-08 | オンコセラピー・サイエンス株式会社 | ヒト結腸癌に関連する遺伝子およびポリペプチド |
| WO2004018667A1 (ja) | 2002-08-26 | 2004-03-04 | Kirin Beer Kabushiki Kaisha | ペプチド及びこれを含む医薬 |
| CN101139392B (zh) | 2002-09-12 | 2012-12-26 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
| DE602004015064D1 (de) | 2003-01-06 | 2008-08-28 | Wyeth Corp | Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs |
| PL1620456T3 (pl) * | 2003-04-18 | 2014-06-30 | Ose Pharma Int Sa | Peptydy antygenu związanego z nowotworem HLA-A2 i kompozycje |
| AU2006273192B2 (en) * | 2005-07-27 | 2011-09-01 | Oncotherapy Science, Inc. | Colon cancer related gene TOM34 |
| SI1760089T1 (sl) * | 2005-09-05 | 2009-12-31 | Immatics Biotechnologies Gmbh | S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku |
| TWI610939B (zh) * | 2007-02-21 | 2018-01-11 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| TW201425333A (zh) * | 2007-04-11 | 2014-07-01 | Oncotherapy Science Inc | 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗 |
| MX2011007963A (es) * | 2009-03-18 | 2011-08-17 | Oncotherapy Science Inc | Peptidos neil3 y vacunas que incluyen los mismos. |
-
2011
- 2011-11-25 TW TW100143251A patent/TWI618541B/zh not_active IP Right Cessation
- 2011-11-25 US US13/990,766 patent/US9125849B2/en active Active
- 2011-11-25 SG SG10201509823WA patent/SG10201509823WA/en unknown
- 2011-11-25 NZ NZ61136111A patent/NZ611361A/en not_active IP Right Cessation
- 2011-11-25 CN CN201180066777.2A patent/CN103339253B/zh not_active Expired - Fee Related
- 2011-11-25 MY MYPI2013700903A patent/MY166516A/en unknown
- 2011-11-25 MX MX2013006014A patent/MX344586B/es active IP Right Grant
- 2011-11-25 AU AU2011336019A patent/AU2011336019B2/en not_active Ceased
- 2011-11-25 DK DK11846000.5T patent/DK2646546T3/en active
- 2011-11-25 JP JP2013525055A patent/JP6064186B2/ja active Active
- 2011-11-25 BR BR112013013158A patent/BR112013013158B1/pt not_active IP Right Cessation
- 2011-11-25 PH PH1/2013/501105A patent/PH12013501105A1/en unknown
- 2011-11-25 ES ES11846000.5T patent/ES2677118T3/es active Active
- 2011-11-25 EP EP11846000.5A patent/EP2646546B1/en active Active
- 2011-11-25 EA EA201390811A patent/EA028216B1/ru not_active IP Right Cessation
- 2011-11-25 WO PCT/JP2011/006551 patent/WO2012073459A1/en not_active Ceased
- 2011-11-25 UA UAA201307324A patent/UA110119C2/uk unknown
- 2011-11-25 CN CN201510490693.1A patent/CN105111281A/zh active Pending
- 2011-11-25 SG SG2013040415A patent/SG190407A1/en unknown
- 2011-11-25 KR KR1020137017079A patent/KR102004900B1/ko not_active Expired - Fee Related
- 2011-11-25 CA CA2819463A patent/CA2819463C/en active Active
- 2011-12-02 AR ARP110104514 patent/AR084095A1/es unknown
-
2013
- 2013-04-30 IL IL226068A patent/IL226068B/en active IP Right Grant
- 2013-05-28 ZA ZA2013/03886A patent/ZA201303886B/en unknown
- 2013-07-02 CO CO13155530A patent/CO6862100A2/es active IP Right Grant
-
2015
- 2015-07-27 US US14/810,287 patent/US9585948B2/en not_active Expired - Fee Related
-
2016
- 2016-06-20 JP JP2016121469A patent/JP2016222676A/ja not_active Withdrawn
-
2017
- 2017-01-23 US US15/412,760 patent/US20170198010A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2920197T3 (da) | Prolinlåste sammenhæftede peptider og anvendelser deraf | |
| EP2870505A4 (en) | TRANSPARENT GLOSS AND GLOSS PROTECTION STRUCTURES | |
| CO6821892A2 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| DK2903600T3 (da) | Virusholdig formulering og anvendelse deraf | |
| CO7020859A2 (es) | Anticuerpos anti-cd134 (ox40) y usos de los mismos | |
| ES2660615T8 (es) | Vectores de CMVH y CMVRh recombinantes y usos de los mismos | |
| EP2930714A4 (en) | Singing voice synthesizing system and singing voice synthesizing method | |
| DK2855736T3 (da) | Elektrolysator og energisystem | |
| DK2779851T3 (da) | Aerosolgenererende indretning og system | |
| IL226307A0 (en) | Compounds and methods for treating pain | |
| HUE045127T2 (hu) | Aeroszol-fejlesztõ rendszer szivárgás-megakadályozással | |
| DK2920313T3 (da) | Rekombinante adenovira og anvendelse deraf | |
| DK3321287T3 (da) | Fusionsproteiner og kombinationsvacciner | |
| DK2552434T3 (da) | Peptider og anvendelse deraf | |
| DK2872419T3 (da) | Fordelingsbeholder og tilsvarende fremgangsmåde | |
| IL232262A (en) | Therapeutic agents and uses thereof | |
| CO6870003A2 (es) | Vacunas bovinas y métodos | |
| FI20116089L (fi) | Järjestely ja laite | |
| EP3494989C0 (en) | COMPOSITE ANTIGEN SEQUENCES AND VACCINES | |
| EP2876161A4 (en) | VACCINE | |
| DK2883954T3 (da) | Peptidbibliotek og anvendelse deraf | |
| CO6821894A2 (es) | Peptidos de amilina y derivados y usos de los mismos | |
| SMT201700046B (it) | Micobatterio ricombinante come vaccino | |
| EP2855506A4 (en) | PEPTIDE AND USE THEREOF | |
| CL2014002180A1 (es) | Peptidos antomicrobianos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |